e-Drug3D
1507
cas 478296-72-9
CLASS
NERVOUS SYSTEM
MODERATE-TO-SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS) IN ADULTS
ANTIEPILEPTIC
POSTHERPETIC NEURALGIA (PHN)
GABAB AGONIST
ROUTE (list)
ORAL
ATC code
N02BF01
PK parameters
Solubility
0.5 MILLIGRAM / MILLILITER
TARGET VOLTAGE-GATED CALCIUM CHANNEL (PMID26680202)
Voltage-dependent calcium channel subunit alpha-2,delta-1 UNIPROT P54289 CACNA2D1
Voltage-dependent calcium channel subunit alpha-2,delta-2 UNIPROT Q9NY47 CACNA2D2
Formula:
C16H27NO6
Calculated chemical properties:
MW 328.38
NB_atoms 23
XLogP 1.35
PSA 90.227
NB_HD 1
NB_HA 7
fsp3 0.81
Lipinski(0=no;1=yes) 1
NB_atoms 23
XLogP 1.35
PSA 90.227
NB_HD 1
NB_HA 7
fsp3 0.81
Lipinski(0=no;1=yes) 1
FDA
NDA 022399 (label) INN (GABAPENTIN ENACARBIL) HORIZANT (AZURITY) APPROVAL= AP YEAR= 2011 NEWMOLECULARENTITY
NDA 213501 (pdf not found) INN (GABAPENTIN ENACARBIL) GABAPENTIN ENCARBIL (GLENMARK PHARMS LTD) APPROVAL= TA YEAR= 2020
NDA 220420 (pdf not found) INN (GABAPENTIN ENACARBIL) GABAPENTIN ENACARBIL (ANNORA PHARMA PRIVATE LIMITED) APPROVAL= TA YEAR= 2026
NDA 022399 (label) INN (GABAPENTIN ENACARBIL) HORIZANT (AZURITY) APPROVAL= AP YEAR= 2011 NEWMOLECULARENTITY
NDA 213501 (pdf not found) INN (GABAPENTIN ENACARBIL) GABAPENTIN ENCARBIL (GLENMARK PHARMS LTD) APPROVAL= TA YEAR= 2020
NDA 220420 (pdf not found) INN (GABAPENTIN ENACARBIL) GABAPENTIN ENACARBIL (ANNORA PHARMA PRIVATE LIMITED) APPROVAL= TA YEAR= 2026